- Home
- BPMC vs ESAB Comparison
BPMC vs ESAB Comparison
Compare BPMC & ESAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPMC
- ESAB
- Stock Information
- Founded
- BPMC 2008
- ESAB 1904
- Country
- BPMC United States
- ESAB United States
- Employees
- BPMC N/A
- ESAB N/A
- Industry
- BPMC Biotechnology: Pharmaceutical Preparations
- ESAB Office Equipment/Supplies/Services
- Sector
- BPMC Health Care
- ESAB Industrials
- Exchange
- BPMC Nasdaq
- ESAB Nasdaq
- Market Cap
- BPMC 6.7B
- ESAB 7.1B
- IPO Year
- BPMC 2015
- ESAB N/A
- Fundamental
- Price
- BPMC $111.96
- ESAB $128.54
- Analyst Decision
- BPMC Buy
- ESAB Buy
- Analyst Count
- BPMC 19
- ESAB 7
- Target Price
- BPMC $122.72
- ESAB $133.43
- AVG Volume (30 Days)
- BPMC 789.4K
- ESAB 225.5K
- Earning Date
- BPMC 02-13-2025
- ESAB 02-27-2025
- Dividend Yield
- BPMC N/A
- ESAB 0.23%
- EPS Growth
- BPMC N/A
- ESAB 20.29
- EPS
- BPMC N/A
- ESAB 4.26
- Revenue
- BPMC $434,415,000.00
- ESAB $2,759,395,000.00
- Revenue This Year
- BPMC $108.09
- ESAB N/A
- Revenue Next Year
- BPMC $39.34
- ESAB $4.39
- P/E Ratio
- BPMC N/A
- ESAB $30.14
- Revenue Growth
- BPMC 100.93
- ESAB 0.36
- 52 Week Low
- BPMC $72.24
- ESAB $85.79
- 52 Week High
- BPMC $121.90
- ESAB $135.97
- Technical
- Relative Strength Index (RSI)
- BPMC 71.32
- ESAB 64.84
- Support Level
- BPMC $103.67
- ESAB $113.47
- Resistance Level
- BPMC $107.88
- ESAB $120.09
- Average True Range (ATR)
- BPMC 4.24
- ESAB 3.35
- MACD
- BPMC 2.43
- ESAB 1.09
- Stochastic Oscillator
- BPMC 97.93
- ESAB 98.20
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
About ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.8 billion in revenue in 2023.